- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00909363
Thrombocytopenia and Bleeding in Wiskott-Aldrich Syndrome (WAS) Patients (WAS)
Effects Of Eltrombopag On Thrombocytopenia, Platelet Function and Bleeding In Patients With Wiskott-Aldrich Syndrome/X-Linked Thrombocytopenia.
Study Overview
Status
Conditions
Detailed Description
Wiskott Aldrich Syndrome is an X-linked disease characterized by immunodeficiency, eczema and thrombocytopenia; a milder form of the disease known as X-Linked thrombocytopenia also exists. The thrombocytopenia in both WAS and XLT is characterized by: severe thrombocytopenia with platelet counts frequently less than 10-30,000/ul; small platelets which may be dysfunctional; and, as a result, a high rate of serious bleeding including intracranial hemorrhage.
Because eltrombopag has been shown to be remarkably efficacious in substantially increasing platelet counts in a high percentage of ITP patients, this study seeks to effectively treat patients who exhibit similar pathologies, as well as evaluate the state of platelets in patients with WAS and relate it to clinical bleeding. It also aims to demonstrate whether eltrombopag administered daily will enhance stem cell function, increase platelet production and platelet count, and reduce bleeding in patients with WAS.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10065
- Weill Cornell Medical College
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
In order to be eligible for study entry, subjects must comply with the following:
- Males from 3 months old to 80 years old
- Signed written informed consent obtained prior to study entry
- Clinical diagnosis of WAS or XLT
- Platelet levels less than 100 x 109/L
- Adequate renal and hepatic function (creatinine and bilirubin less than or equal to 1.5 x IULN, AST and ALT less than or equal to 2.5 x IULN)
Exclusion Criteria:
Any patient is ineligible for study entry if he/she:
- Over the age of 80
- Women (only males are eligible)
- fertile men who are not practicing or who are unwilling to practice birth control while enrolled in the study or until at least 6 months after treatment
- Aspirin, aspirin-containing compounds, salicylates, non-steroidal anti-inflammatory medications (NSAIDS), clopidogrel or ticlopidine, warfarin or other vitamin K antagonists, unfractionated or low molecular heparin within 7 days of first infusion
- Red blood cell transfusion in the past four weeks
- Elevated (> 1.5 x ULN) prothrombin time (PT) or partial thromboplastin time (PTT)
- New York Heart Classification III or IV heart disease. Other severe cardiovascular or cardiopulmonary disease, including COPD.
- Known HIV infection, hepatitis B or C infection
- Any infection requiring antibiotic treatment within 3 days
- Other concurrent medical or psychiatric conditions that, in the Investigator's opinion, may be likely to confound study interpretation or prevent completion of study procedures and follow-up examinations.
- Prior malignancy with less than a 5-year disease-free interval, excluding nonmelanoma skin cancers and carcinoma in situ of the cervix
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: WAS patients receiving Promacta
Promacta® is commercially available in 12.5 mg, 25 mg, 50 mg, and 75 mg tablets.
For this study, for young children unable to swallow a tablet, eltrombopag powder for oral suspension (Eltrombopag PfOS) will be used.
PfOS is only available for investigational use at 20mg.
Each sachet contains eltrombopag equivalent to 20mg per gm of powder and is reconstituted to a total of 10 ml so that the concentration is 2 mg/ml.
|
WAS Patients receiving treatment will start on 1 mg/kg of eltrombopag daily and be seen weekly for 12 weeks. Dose adjustment will be based on the weekly monitoring of the platelet count as utilized in ongoing studies in ITP as well as on liver tests. they will also have diagnostic blood testing prior to initiating treatment
Other Names:
|
Experimental: WAS patients for blood drawing only
WAS patients not receiving treatment to serve as subjects for platelet parameter studies blood drawing once only
|
blood will be drawn for platelet parameters in WAS patients not receiving treatment either because they declined or because they were ineligible
|
Placebo Comparator: healthy children for blood drawing only
healthy children having blood obtained once as controls for platelet parameters study
|
blood will be drawn once in healthy children as controls for platelet parameters
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
How Many WAS Patients Will Achieve Platelet Counts Above 50,000/ul.
Time Frame: 12 weeks
|
number of WAS patients achieving this increase to > 50,000/uL without rescue medication in the previous 3 weeks during eltrombopag treatment
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Patients With Wiskott-Aldrich Syndrome (WAS) With Grade 3 or Higher Bleeding or SAE (on WHO Scale)
Time Frame: 12 Weeks
|
number of patients with bleeding SAEs while on treatment and/or number of patients with grade 3 or higher bleeding on WHO (World Health Organization) scale: the scale is from 1 to 5 with 5 = fatality and 1=very little bleeding
|
12 Weeks
|
How Many Patients With WAS Had Abnormal Platelet Function Including Activation
Time Frame: 12 weeks
|
in how many patients with WAS were platelets dysfunctional or activated before treatment as measured by flow cytometry to a substantial degree and the same after treatment with eltrombopag
|
12 weeks
|
How Many Patients With WAS Had Substantially Increased Platelet Production After Eltrombopag
Time Frame: 12 weeks
|
in how many patients with WAS did eltrombopag increase platelet production as measured by the immature platelet fraction (IPF), a variable derived from the Sysmex auto analyzer, which is considered to be a measure of newly formed platelets ie reticulated platelets
|
12 weeks
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: James B Bussel, MD, Weill Medical College of Cornell University
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Disease
- Hematologic Diseases
- Blood Coagulation Disorders, Inherited
- Hemorrhagic Disorders
- Genetic Diseases, Inborn
- Genetic Diseases, X-Linked
- Blood Coagulation Disorders
- Blood Platelet Disorders
- Leukopenia
- Leukocyte Disorders
- Primary Immunodeficiency Diseases
- Lymphopenia
- Syndrome
- Hemorrhage
- Thrombocytopenia
- Wiskott-Aldrich Syndrome
Other Study ID Numbers
- 0801009600
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bleeding
-
Ethicon, Inc.Guangzhou Bioseal Biotechnology Co., Ltd.Completed
-
Waihong ChungUnknownMetoclopramide, Azithromycin, or Nondrug Pretreatment for UGIB to Reduce Second Endoscopy (MANPURSE)Upper Gastrointestinal Bleeding | Gastro Intestinal BleedingUnited States
-
Ottawa Hospital Research InstituteRecruitingGastroIntestinal Bleeding | Anticoagulant-induced BleedingCanada
-
Ethicon, Inc.CompletedHemorrhage | Soft Tissue Bleeding | Hepatic Parenchyma BleedingUnited Kingdom, Belgium
-
Hyloris DevelopmentsRecruitingBleeding From Teeth | Bleeding ProphylaxisSpain, United States, Belgium, Croatia, Hungary, Romania
-
Boston Children's HospitalBaylor College of Medicine; Children's Hospital of Philadelphia; Ann & Robert... and other collaboratorsRecruitingUpper Gastrointestinal Bleeding | Gastro Intestinal BleedingUnited States
-
Wake Forest University Health SciencesCompletedBleeding ComplicationUnited States
-
Chinese University of Hong KongCompletedGastrointestinal Bleeding | Bleeding Peptic Ulcer | Active BleedingChina
-
Chinese University of Hong KongBeijing Friendship Hospital; The First Affiliated Hospital of Soochow University and other collaboratorsCompletedAcute Upper Gastrointestinal Bleeding | Tumor BleedingHong Kong, China, Australia
-
Women and Infants Hospital of Rhode IslandActive, not recruitingAbnormal Uterine Bleeding | Abnormal Uterine Bleeding, Ovulatory Dysfunction | Abnormal Uterine Bleeding, Endometrial Hemostatic DysfunctionUnited States
Clinical Trials on Promacta
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedMyelodysplastic Syndromes | ThrombocytopeniaUnited States
-
M.D. Anderson Cancer CenterGlaxoSmithKlineCompleted
-
Anjali PawarRecruitingSolid Tumor | Solid Tumor, ChildhoodUnited States
-
GlaxoSmithKlineCompletedPurpura, Thrombocytopaenic, IdiopathicUnited States, Bulgaria, Italy, Peru, Russian Federation, Canada, France, Germany, Hong Kong, Spain, Sweden, United Kingdom, Hungary, Poland, Ukraine, Czech Republic, India, Australia, Tunisia, Puerto Rico, Pakistan
-
H. Lee Moffitt Cancer Center and Research InstituteGlaxoSmithKlineTerminatedThrombocytopenia | Myelodysplastic Syndrome (MDS)United States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedSevere Aplastic Anemia (SAA)United States
-
M.D. Anderson Cancer CenterNovartis PharmaceuticalsCompleted
-
IRCCS Policlinico S. MatteoGlaxoSmithKline; University of Pavia; Azienda Ospedaliera di Padova; Azienda Ospedaliera... and other collaboratorsCompletedBlood Platelet DisordersItaly
-
Novartis PharmaceuticalsCompletedThrombocytopaeniaUnited States, Belgium, Canada, Hong Kong, Argentina, Brazil, Czechia, Germany, Greece, Israel, Netherlands, Spain, Thailand, Hungary, Ireland, Italy, Mexico, Taiwan, Korea, Republic of, Poland, Russian Federation, Puerto Rico
-
Weill Medical College of Cornell UniversityNovartisTerminatedImmune ThrombocytopeniaUnited States